Market Overview:
The global ovarian cancer therapeutics market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of ovarian cancer, rising awareness about early diagnosis and treatment options, and technological advancements in the field of ovarian cancer therapeutics. The global ovarian cancer therapeutics market is segmented on the basis of type into PARP inhibitors, PD-L1 inhibitors, and angiogenesis inhibitors. The PARP inhibitor segment is expected to account for the largest share of the global ovarian cancer therapeutics market in 2018 owing to their high efficacy in treating advanced-stage cancers. The PD-L1 inhibitor segment is projected to grow at a higher CAGR than other segments during the forecast period due its potential benefits such as improved overall survival rates and longer progression-free survival rates compared with chemotherapy regimens alone.
Product Definition:
Ovarian cancer therapeutics are the drugs and treatments used to fight ovarian cancer. Ovarian cancer is a type of cancer that starts in the ovaries. It is the fifth most common type of cancer in women. Each year, about 22,000 women are diagnosed with ovarian cancer and 14,000 die from it. The five-year survival rate for those with ovarian cancers is about 47%.
PARP:
Polymerase chain reaction (PCR) is a technique wherein multiple copies of a specific DNA sequence are generated from a single original DNA molecule. PARP is an enzyme that acts as the molecular catalyst in the process called polymerase chain reaction.
PD-L1:
PD-L1 is a protein that acts as an immune checkpoint molecule. It is found on the surface of most cytotoxic T cells and helps them to recognize and attack cancer cells. PD-L1 expression has been observed to be higher in ovarian carcinoma tissues than in normal tissues, which makes it an attractive target for therapeutic intervention.
Application Insights:
Based on application, the market is segmented into hospital-based, research and into private practice. Hospital-based ovarian cancer therapeutics held the largest share in 2017 owing to increasing prevalence of cancer across the globe. Ovarian cancer is highly prevalent among women than men; around 1 in 5 women develop it during their lifetime as compared to only 1 in 15 men. This leads to high demand for hospital-based OVARIAN CANCER THERAPEUTICS market and this trend is expected to continue over next few years due largely to increase number of clinical trials being conducted for various drugs used against ovarian tumor types.
The research segment held a significant share in 2017 owing primarily due to extensive R&D initiatives undertaken by key players such as Merck KGaA, Pfizer Inc., Johnson & Johnson Pharmaceuticals LLC., Novartis AG and Eli Lilly & Co.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, increased research activities, and high healthcare expenditure in this region. The Asia Pacific is expected to witness lucrative growth over the forecast period owing to increasing awareness about early diagnosis and rising disposable income coupled with government support for R&D activities pertaining ovarian cancer treatment. In addition, growing number of clinical trials being conducted in Asian countries will drive growth further. Moreover, increasing incidence rate of gynecological cancers among women is also contributing toward regional market growth (Ovarian Cancer Research Fund International 2016).
In November 2015; Japan’s Ministry of Health & Welfare (MHLW) announced that it would provide funds worth USD X million for MSC-based therapy research project which was initiated by Dr Toru Takei from Chiba University Hospital (CTUH).
Growth Factors:
- Increasing incidence of ovarian cancer
- Rising demand for better and advanced treatment options for ovarian cancer
- Growing awareness about ovarian cancer and its symptoms
- Technological advancements in the field of ovarian cancer therapeutics
- Availability of government funding and support for research on ovarian cancer
Scope Of The Report
Report Attributes
Report Details
Report Title
Ovarian Cancer Therapeutics Market Research Report
By Type
PARP, PD-L1, Angiogenesis Inhibitors
By Application
Hosptial, Research
By Companies
Bristol Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline Plc, Janssen Pharmaceuticals, Genentech Inc., Astra Zeneca, Boehringer Ingelheim GmbH, Hoffmann La Roche Ltd.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
246
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Ovarian Cancer Therapeutics Market Report Segments:
The global Ovarian Cancer Therapeutics market is segmented on the basis of:
Types
PARP, PD-L1, Angiogenesis Inhibitors
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hosptial, Research
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bristol Myers Squibb Company
- Eli Lilly and Company
- GlaxoSmithKline Plc
- Janssen Pharmaceuticals
- Genentech Inc.
- Astra Zeneca
- Boehringer Ingelheim GmbH
- Hoffmann La Roche Ltd.
Highlights of The Ovarian Cancer Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- PARP
- PD-L1
- Angiogenesis Inhibitors
- By Application:
- Hosptial
- Research
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Ovarian Cancer Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Ovarian cancer therapeutics are medications or treatments that are used to treat ovarian cancer.
Some of the major players in the ovarian cancer therapeutics market are Bristol Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline Plc, Janssen Pharmaceuticals, Genentech Inc., Astra Zeneca, Boehringer Ingelheim GmbH, Hoffmann La Roche Ltd..
The ovarian cancer therapeutics market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Ovarian Cancer Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Ovarian Cancer Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Ovarian Cancer Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Ovarian Cancer Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Ovarian Cancer Therapeutics Market Size & Forecast, 2020-2028
4.5.1 Ovarian Cancer Therapeutics Market Size and Y-o-Y Growth
4.5.2 Ovarian Cancer Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 PARP
5.2.2 PD-L1
5.2.3 Angiogenesis Inhibitors
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hosptial
6.2.2 Research
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Ovarian Cancer Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Ovarian Cancer Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 PARP
9.6.2 PD-L1
9.6.3 Angiogenesis Inhibitors
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hosptial
9.10.2 Research
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 PARP
10.6.2 PD-L1
10.6.3 Angiogenesis Inhibitors
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hosptial
10.10.2 Research
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 PARP
11.6.2 PD-L1
11.6.3 Angiogenesis Inhibitors
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hosptial
11.10.2 Research
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 PARP
12.6.2 PD-L1
12.6.3 Angiogenesis Inhibitors
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hosptial
12.10.2 Research
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 PARP
13.6.2 PD-L1
13.6.3 Angiogenesis Inhibitors
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hosptial
13.10.2 Research
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Ovarian Cancer Therapeutics Market: Competitive Dashboard
14.2 Global Ovarian Cancer Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bristol Myers Squibb Company
14.3.2 Eli Lilly and Company
14.3.3 GlaxoSmithKline Plc
14.3.4 Janssen Pharmaceuticals
14.3.5 Genentech Inc.
14.3.6 Astra Zeneca
14.3.7 Boehringer Ingelheim GmbH
14.3.8 Hoffmann La Roche Ltd.
